RecruitingPhase 1NCT06904066
Blood
Chronic myelomonocytic leukemia
72
studies recruiting now
as of 7 Sept 2026
644
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
25 Nov 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT03383575
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RecruitingPhase 1 / Phase 2NCT05849662
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RecruitingPhase 2NCT07249346
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 1 / Phase 2NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 72 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Chronic myelomonocytic leukemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Chronic myelomonocytic leukemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (ETV6, ASXL1, SRSF2).
Treatments being studied
2 approved treatments and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Azacitidine (Azacitidine)Approved: Decitabine (Dacogen)
Phase 3Lonafarnib (Zokinvy)
Phase 3Rigosertib Sodium (Estybon)
Phase 2Tipifarnib
Phase 2Cobimetinib
Phase 2Venetoclax (Venclexta)
Phase 2Lenalidomide (Lenalidomide accord)
Phase 2Clofarabine (Clolar)
Phase 2Cyclophosphamide (Cyclophosphamide)
+ 4 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).